Clinical trials
Withdrawn Liver Neoplasms trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
49 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 1 |
| 2005 | 2 |
| 2006 | 2 |
| 2007 | 3 |
| 2009 | 1 |
| 2010 | 1 |
| 2011 | 1 |
| 2012 | 3 |
| 2013 | 1 |
| 2014 | 3 |
| 2015 | 2 |
| 2016 | 4 |
| 2017 | 2 |
| 2018 | 3 |
| 2019 | 2 |
| 2020 | 2 |
| 2021 | 1 |
| 2022 | 2 |
| 2023 | 5 |
| 2025 | 4 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Withdrawn | 49 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| M.D. Anderson Cancer Center | 5 |
| National Cancer Institute (NCI) | 3 |
| Washington University School of Medicine | 3 |
| Boston Scientific Corporation | 2 |
| H. Lee Moffitt Cancer Center and Research Institute | 2 |
| Jonsson Comprehensive Cancer Center | 2 |
| Medical College of Wisconsin | 2 |
| Memorial Sloan Kettering Cancer Center | 2 |
| Mirror Biologics, Inc. | 2 |
| University of Louisville | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Liver Neoplasms | 49 |
| Carcinoma, Hepatocellular | 23 |
| Colorectal Neoplasms | 5 |
| Neoplasm Metastasis | 5 |
| Pancreatic Neoplasms | 5 |
| Cholangiocarcinoma | 4 |
| Stomach Neoplasms | 4 |
| Lung Neoplasms | 3 |
| Neoplasms | 3 |
| Colonic Neoplasms | 2 |
Trials
Showing 1 to 25 of 49. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.